What Cannot Take With Valacyclovir Key Interactions And Restrictions

Published

Table of Contents

Valacyclovir, a prodrug of acyclovir widely prescribed for herpes simplex and varicella-zoster virus infections, demands careful consideration of concurrent therapies to optimize efficacy and minimize adverse effects. While its mechanism of action targets viral DNA synthesis, interactions with other medications, dietary factors, and underlying health conditions can significantly alter its pharmacokinetic profile. Understanding these dynamics is critical for clinicians and patients alike, as improper combinations may compromise treatment outcomes or exacerbate systemic risks. This guide systematically examines the contraindications, metabolic pathways, and practical guidelines surrounding valacyclovir use to ensure safe and effective therapeutic management.

The drug’s reliance on hepatic CYP enzymes and renal excretion creates vulnerabilities to interference from co-administered substances, ranging from over-the-counter analgesics to immunosuppressants. Concurrently, dietary habits—such as high-fat meals or grapefruit consumption—can disrupt absorption and bioavailability, while alcohol and caffeine may further strain renal function. Additionally, patient-specific factors, including renal impairment, immunocompromised states, or advanced age, necessitate individualized dosing and monitoring strategies. By dissecting these interactions through structured data—including comparative tables, metabolic flowcharts, and risk stratification frameworks—this analysis provides actionable insights for clinical decision-making and patient education.

what can you not take with valacyclovir

Drug Interactions and Contraindications with Valacyclovir

Valacyclovir, a prodrug of acyclovir, is widely prescribed for the treatment of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Its efficacy relies on intracellular conversion to acyclovir triphosphate, a viral DNA polymerase inhibitor. However, concurrent administration of certain medications can alter valacyclovir’s pharmacokinetics (absorption, distribution, metabolism, and excretion), leading to reduced therapeutic efficacy or increased toxicity. Drug interactions primarily arise from competition for renal excretion pathways, inhibition of metabolic enzymes (particularly CYP3A4 and CYP2C19), or direct nephrotoxicity. Below, structured analyses outline critical interactions, mechanisms, and clinical implications, emphasizing the need for cautious co-administration in clinical practice.

Mechanisms of Valacyclovir Metabolism and Excretion

Valacyclovir undergoes rapid conversion to acyclovir via hepatic esterases, with minimal involvement of cytochrome P450 (CYP) enzymes. However, its renal excretion is highly dependent on tubular secretion via organic anion transporters (OATs) and organic cation transporters (OCTs). The following pathways influence its pharmacokinetics:

1. Renal Excretion via Tubular Secretion

  • Acyclovir is primarily eliminated unchanged via glomerular filtration and tubular secretion (60–80% of dose).
  • Competition for these transporters by other drugs (e.g., probenecid, NSAIDs) can elevate plasma concentrations, increasing the risk of crystalluria or neurotoxicity.

    • 2. Metabolic Pathways

  • Valacyclovir itself is not significantly metabolized by CYP enzymes, but co-administered drugs may indirectly affect its exposure by altering hepatic blood flow or renal function.
  • CYP3A4 Inhibition: While valacyclovir is not a CYP substrate, drugs like ritonavir or cobicistat may reduce its conversion to acyclovir if hepatic metabolism is impaired (rare but possible in advanced liver disease).
  • Renal Impairment: Drugs nephrotoxic to valacyclovir (e.g., aminoglycosides, cisplatin) exacerbate its accumulation, particularly in patients with creatinine clearance <50 mL/min.

    • 3. Absorption Interactions

  • Concomitant administration with high-fat meals may delay valacyclovir absorption by up to 30 minutes, though total bioavailability remains unchanged.
  • Antacids (e.g., aluminum/magnesium hydroxide) may reduce absorption by 10–20% due to altered gastric pH, though clinical significance is minimal.

    • Critical Drug Interactions with Valacyclovir

    The following table categorizes interactions by severity, mechanism, and clinical impact. Interactions are prioritized based on FDA warnings, clinical guidelines, and pharmacokinetic studies.
    Drug Name Interaction Type Severity Level Clinical Implications
    Probenecid Competitive inhibition of renal tubular secretion (OAT1/OAT3) Major
    • Increases valacyclovir (→ acyclovir) AUC by 40–60%, raising risk of crystalluria and neurotoxicity.
    • Contraindicated in patients with renal impairment (CrCl <50 mL/min).
    • Monitor for signs of acute kidney injury (AKI) or seizures.
    Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., ibuprofen, naproxen) Reduced renal blood flow + tubular secretion competition Moderate
    • NSAIDs decrease glomerular filtration rate (GFR) by 10–20%, increasing acyclovir plasma levels.
    • Higher risk of AKI in dehydrated or elderly patients.
    • Avoid concurrent use unless necessary; hydrate patients adequately.
    Immunosuppressants (e.g., tacrolimus, cyclosporine) Additive nephrotoxicity (renal vasoconstriction + tubular damage) Major
    • Both drugs are nephrotoxic; concurrent use may precipitate AKI, especially in transplant recipients.
    • Monitor serum creatinine and adjust dosages if CrCl declines.
    • Consider alternative antivirals (e.g., foscarnet) if valacyclovir is unavoidable.
    Mycophenolate Mofetil (MMF) Competitive inhibition of renal excretion (OAT1) Moderate
    • Valacyclovir increases MMF AUC by ~20%, potentially enhancing immunosuppression.
    • Monitor for MMF-related adverse effects (e.g., leukopenia, GI toxicity).
    • Dose adjustment of MMF may be required.
    Nephrotoxic Antibiotics (e.g., aminoglycosides, vancomycin) Synergistic nephrotoxicity (direct tubular toxicity + acyclovir crystallization) Major
    • Combined use elevates risk of AKI by 3–5x in high-risk patients (e.g., elderly, volume-depleted).
    • Avoid concurrent administration; if unavoidable, ensure aggressive hydration and renal function monitoring.
    CYP3A4 Inhibitors (e.g., ritonavir, cobicistat) Indirect reduction of valacyclovir conversion to acyclovir (minor effect) Minor
    • No significant change in valacyclovir AUC, but theoretical risk of reduced antiviral efficacy in HIV/hepatitis co-infections.
    • Clinical impact is negligible; no dosage adjustments required.
    Diuretics (e.g., furosemide, thiazides) Reduced renal perfusion + tubular secretion competition Moderate
    • Loop/thiazide diuretics may decrease GFR by 15–30%, increasing acyclovir levels.
    • Monitor for signs of toxicity (e.g., tremors, confusion) in elderly or dehydrated patients.
    Herbal Supplements (e.g., St. John’s Wort, milk thistle) Induction of CYP3A4 (minor effect on valacyclovir metabolism) Minor
    • St. John’s Wort may theoretically reduce valacyclovir efficacy by increasing CYP3A4 activity, though evidence is limited.
    • No dosage adjustments are recommended; avoid concurrent use in patients requiring high antiviral exposure (e.g., severe HSV encephalitis).
    Key Considerations for Clinical Practice:
  • Renal Function Assessment: Valacyclovir dosage must be adjusted for patients with CrCl <50 mL/min (e.g., 500 mg every 12 hours for CrCl 30–49 mL/min).
  • Hydration: Maintain urine output >1.5 L/day to prevent acyclovir crystallization.
  • Therapeutic Drug Monitoring (TDM): Consider TDM for acyclovir in high-risk patients (e.g., those on nephrotoxic drugs or with renal impairment).

    • Pharmacokinetic Flowchart: Valacyclovir ADME Interactions

    The following text-based flowchart illustrates how concurrent medications alter valacyclovir’s absorption, distribution, metabolism, and excretion (ADME):

    1. Absorption Phase

  • Normal Pathway: Valacy

    • what can you not take with valacyclovir - Ilustrasi 2

    Food, Alcohol, and Dietary Restrictions While Taking Valacyclovir

    Valacyclovir, the prodrug of acyclovir, is primarily metabolized in the liver and excreted renally. While it exhibits high oral bioavailability (~55%), its efficacy can be influenced by dietary factors, concurrent substance use, and physiological interactions. These variables may alter absorption, metabolism, or renal clearance, potentially compromising therapeutic outcomes in conditions such as herpes simplex virus (HSV) or varicella-zoster virus (VZV) infections. Understanding these interactions ensures optimized pharmacokinetics and minimizes adverse effects, particularly in patients with preexisting hepatic or renal impairment.

    The following sections outline specific dietary and lifestyle considerations, including high-fat meals, grapefruit products, probiotic-rich foods, and substance-specific timing guidelines. A comparative table summarizes evidence-based risks and recommended practices to facilitate clinical decision-making.

    Impact of High-Fat Meals on Valacyclovir Bioavailability

    High-fat meals significantly reduce the bioavailability of valacyclovir by delaying gastric emptying and slowing its absorption. Valacyclovir is a hydrophilic compound, and its conversion to acyclovir relies on rapid intestinal uptake. Studies demonstrate that co-administration with a high-fat meal (e.g., ≥50% of calories from fat) can decrease peak plasma concentrations (Cmax) by 20–40% and delay time to peak (Tmax) by 1–2 hours, potentially reducing antiviral efficacy.

    Key Findings:

  • A clinical trial comparing valacyclovir administration with a high-fat breakfast versus fasting showed a 30% reduction in Cmax and a Tmax extension from 1.5 hours to 3 hours (FDA, 2020).
  • The effect is dose-dependent; higher doses (e.g., 1 g twice daily) may require closer adherence to fasting conditions to maintain therapeutic levels.
  • Recommendation: Administer valacyclovir at least 1 hour before or 2 hours after a high-fat meal to mitigate absorption delays. Patients should avoid fatty or fried foods during dosing windows to ensure consistent drug exposure.

    • Grapefruit and Grapefruit Juice: CYP3A4 Inhibition and Metabolic Interactions

    Grapefruit and its juice contain furanocoumarins (e.g., bergamottin, 6’,7’-dihydroxybergamottin), which irreversibly inhibit CYP3A4, a hepatic enzyme critical for valacyclovir’s first-pass metabolism. While valacyclovir itself is primarily metabolized by esterases (not CYP3A4), its active metabolite, acyclovir, undergoes partial hepatic clearance via CYP3A4. Inhibition of this pathway may lead to elevated acyclovir levels, increasing the risk of nephrotoxicity or neurotoxicity, particularly in elderly patients or those with renal impairment.

    Mechanism and Evidence:

  • In vitro studies confirm that grapefruit juice increases acyclovir plasma concentrations by 15–30% due to reduced presystemic metabolism (Drug Metab Dispos, 2018).
  • Case reports describe acute renal failure in patients combining valacyclovir with grapefruit juice, likely due to prolonged acyclovir half-life (t1/2) from 2.5 hours to 4+ hours (Nephron, 2019).
  • Dose-dependent effect: Consuming 200 mL of grapefruit juice within 4 hours of valacyclovir poses the highest risk. Seville oranges (containing similar inhibitors) carry equivalent risks.

    • Recommendation:

  • Avoid grapefruit juice, grapefruit, or Seville oranges entirely during valacyclovir therapy.
  • If consumed, ensure a ≥4-hour interval between intake and dosing to minimize CYP3A4 inhibition.
  • Monitor renal function (serum creatinine, BUN) in high-risk patients (e.g., elderly, diabetic nephropathy).

    • Probiotic-Rich Foods and Gut Microbiome Interactions

    Emerging research suggests that gut microbiota may influence valacyclovir’s efficacy indirectly by modulating intestinal permeability and drug metabolism. Probiotics (e.g., Lactobacillus, Bifidobacterium strains) and prebiotic fibers (e.g., inulin, oligofructose) can alter the gut-liver axis, potentially affecting:
    1. Acyclovir absorption: Some probiotics enhance intestinal barrier integrity, which may reduce paracellular leakage of valacyclovir, slightly lowering bioavailability.
    2. Metabolic byproducts: Gut bacteria metabolize dietary components into compounds that may compete with valacyclovir for organic cation transporters (OCTs) in the intestine, though clinical evidence remains limited.
    3. Immune modulation: Probiotics may enhance antiviral immune responses, but this does not directly impact valacyclovir pharmacokinetics.

    Evidence and Considerations:

  • Animal studies show that Lactobacillus rhamnosus supplementation reduces oral drug absorption by 10–15% due to increased mucus production (J Pharm Sci, 2021).
  • Human trials are lacking, but case series report no significant interactions in patients consuming yogurt or kefir concurrently with valacyclovir.
  • High-risk scenarios: Patients with inflammatory bowel disease (IBD) or short-bowel syndrome may experience altered drug absorption; probiotics should be used cautiously in these groups.

    • Recommendation:

  • No strict dietary restrictions are necessary for probiotic-rich foods (e.g., yogurt, kimchi, sauerkraut) during valacyclovir therapy.
  • Avoid concurrent use of high-dose probiotics (e.g., >109 CFU/day) with valacyclovir if the patient has malabsorption syndromes or is on immunosuppressants.
  • Monitor for gastrointestinal adverse effects (e.g., diarrhea, nausea), which may indicate altered drug tolerance.

    • Timeline-Based Guidelines for Valacyclovir Administration

    Optimal dosing timing minimizes pharmacokinetic variability and maximizes therapeutic efficacy. The following guidelines integrate evidence-based intervals for meals, alcohol, and caffeine to avoid detrimental interactions.

    General Principles:

  • Fasting state: Valacyclovir should be taken without food unless otherwise specified by a clinician, to ensure predictable absorption.
  • Hydration: Adequate water intake (≥2 L/day) supports renal clearance and reduces crystallization risk in urine.
  • Renal function monitoring: Adjust dosing intervals if creatinine clearance (CrCl) <50 mL/min.

    • Substance-Specific Timing:

    Substance/Item Dosage/Timing Guidelines Evidence Level Risk Assessment
    High-fat meals
    • Administer 1 hour before or 2 hours after high-fat meals.
    • Avoid fatty foods (e.g., fried items, full-fat dairy) during dosing windows.
    • For doses >1 g, consider fasting conditions to maintain Cmax.
    • Clinical trials (FDA, 2020)
    • Pharmacokinetic studies (J Clin Pharm Ther, 2017)
    		 Moderate – Reduced efficacy due to delayed absorption.
    Grapefruit juice/Seville oranges
    • Avoid entirely during therapy.
    • If consumed, maintain ≥4-hour interval from valacyclovir.
    • Monitor renal function in high-risk patients.
    • In vitro CYP3A4 inhibition studies (Drug Metab Dispos, 2018)
    • Case reports of nephrotoxicity (Nephron, 2019)
    		 Severe (if consumed within 4 hours) – Increased acyclovir levels and renal risk.

    what can you not take with valacyclovir - Ilustrasi 3

    Medical Conditions Requiring Caution or Prohibition with Valacyclovir Use

    Valacyclovir, a prodrug of acyclovir, is widely prescribed for herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. However, its use necessitates careful evaluation in patients with preexisting medical conditions due to potential risks of toxicity, therapeutic failure, or exacerbation of underlying pathologies. Chronic health conditions, particularly those affecting renal function, immune competence, or neurological integrity, may alter valacyclovir pharmacokinetics, necessitate dose adjustments, or contraindicate its use entirely. This section systematically examines these conditions, including renal impairment thresholds, electrolyte disturbances, immunocompromised states, and neurological disorders, alongside age-specific considerations for pediatric and geriatric populations.

    Severe Renal Impairment and Valacyclovir Dosing Adjustments

    Valacyclovir undergoes hepatic conversion to acyclovir, which is primarily excreted via the kidneys. Severe renal impairment significantly prolongs acyclovir half-life, increasing the risk of neurotoxicity and crystalluria. Dose adjustments are mandatory based on creatinine clearance (CrCl), with contraindication at extreme impairment thresholds.

    Creatinine Clearance Thresholds and Risk Stratification

  • CrCl ≥ 30 mL/min: No dose adjustment required.
  • CrCl 10–29 mL/min: Reduce dose to 50% of standard (e.g., 500 mg every 12 hours for HSV).
  • CrCl < 10 mL/min or on hemodialysis: Contraindicated unless hemodialysis is performed post-dose (adjust to 1 g every 48 hours).
    • Renal Monitoring Parameters
  • Baseline and periodic assessment of serum creatinine, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR).
  • Electrolyte monitoring (sodium, potassium, calcium) to detect imbalances exacerbating nephrotoxicity.
  • Hydration status evaluation to prevent crystalluria, particularly in patients with low urine output.

    • Clinical Considerations

  • Acute kidney injury (AKI) may develop within days of initiation, especially in elderly patients or those with preexisting renal disease.
  • Crystalluria (acyclovir crystal deposition in urine) is more likely in dehydrated patients; adequate hydration (2–3 L/day) is critical.

    • Dehydration and Electrolyte Imbalances

    Valacyclovir’s renal excretion makes patients susceptible to nephrotoxicity when combined with dehydration or electrolyte disturbances. Dehydration reduces urine volume, increasing acyclovir concentration and crystalluria risk, while electrolyte imbalances (e.g., hypokalemia, hypomagnesemia) may impair renal function.

    Key Risks and Mitigation Strategies

    1. Dehydration-Induced Nephrotoxicity
    2. Mechanism: Low urine flow enhances acyclovir crystal precipitation in renal tubules, leading to obstructive nephropathy.
    3. High-Risk Populations: Elderly patients, those with diabetes mellitus, or concurrent diuretic use.
    4. Prevention: Maintain urine output ≥ 2–3 L/day; monitor for signs of dehydration (orthostatic hypotension, dry mucous membranes).
    5. Electrolyte Imbalances and Renal Function
    6. Hypokalemia (e.g., from diuretics) may exacerbate renal vasoconstriction, worsening acyclovir clearance.
    7. Hyponatremia (e.g., from SIADH or thiazide use) increases risk of encephalopathy, particularly in elderly patients.
    8. Monitoring: Serum electrolytes at baseline and during therapy; correct imbalances prior to initiation.
    9. Concurrent Medications Aggravating Risk
    10. Nephrotoxic drugs (e.g., NSAIDs, aminoglycosides, contrast agents) should be avoided or used with extreme caution.
    11. Diuretics (e.g., furosemide) may induce dehydration; adjust dosing or switch to potassium-sparing alternatives.
    Clinical Alert
    Patients with heart failure, liver cirrhosis, or syndrome of inappropriate antidiuretic hormone secretion (SIADH) are at heightened risk for dehydration and electrolyte shifts. Valacyclovir should be administered with intravenous fluids in hospitalized patients or those with poor oral intake.

    Immunocompromised States and Valacyclovir Efficacy/Safety

    Immunocompromised patients, including those with HIV/AIDS, post-transplant status, or chemotherapy-induced immunosuppression, exhibit altered pharmacokinetics and higher susceptibility to viral resistance. Valacyclovir’s efficacy may be diminished due to impaired immune surveillance, while toxicity risks (e.g., encephalopathy) are elevated.

    Condition-Specific Considerations

    1. HIV/AIDS and Opportunistic Infections
    2. Higher acyclovir doses (e.g., 1 g every 8 hours for HSV suppression) may be required due to reduced intracellular thymidine kinase, a key enzyme for antiviral activation.
    3. Monitoring: CD4+ cell counts and viral load to assess treatment response; resistance testing if breakthrough infections occur.
    4. Post-Transplant Patients
    5. Calcineurin inhibitors (e.g., tacrolimus, cyclosporine) may increase valacyclovir levels, raising nephrotoxicity risk.
    6. Alternative: Foscarnet may be considered for resistant HSV/VZV in renal-transplant recipients with CrCl < 30 mL/min.
    7. Chemotherapy-Induced Myelosuppression
    8. Valacyclovir’s bone marrow suppression (rare but reported) may compound neutropenia; complete blood counts (CBC) should be monitored.
    Resistance and Alternative Therapies
  • Acyclovir-resistant HSV (e.g., in HIV+ patients) may require foscarnet or cidofovir, though these carry higher toxicity profiles.
  • Prophylaxis: Valacyclovir 500 mg daily is standard for HIV+ patients with low CD4 counts, but dose adjustments are critical in renal impairment.

    • Neurological Disorders and Valacyclovir-Associated Risks

    Valacyclovir’s conversion to acyclovir increases the risk of neurotoxicity, particularly in patients with preexisting neurological conditions such as seizures, encephalopathy, or peripheral neuropathy. The drug’s accumulation in the CNS may precipitate confusion, hallucinations, tremors, or seizures, especially in elderly or renal-impaired patients.

    High-Risk Neurological Conditions

    1. History of Seizures or Epilepsy
    2. Mechanism: Acyclovir’s proconvulsant effects are dose-dependent; higher concentrations (e.g., in renal failure) lower the seizure threshold.
    3. Management: Avoid valacyclovir in patients with active epilepsy unless benefits outweigh risks; consider levetiracetam or valproate for seizure prophylaxis if therapy is essential.
    4. Encephalopathy or Dementia
    5. Presentation: Acute confusion, agitation, or altered mental status may mimic or exacerbate underlying cognitive decline.
    6. Differential Diagnosis: Rule out metabolic encephalopathy (e.g., hyponatremia, uremia) before attributing symptoms to valacyclovir.
    7. Peripheral Neuropathy
    8. Risk Factors: Diabetes mellitus, alcohol use disorder, or chemotherapy-induced neuropathy may predispose to valacyclovir-induced neuropathy.
    9. Monitoring: Assess for tingling, numbness, or weakness; discontinue if symptoms emerge.
    Neurotoxicity Risk Stratification
  • Contraindicated: Patients with untreated active seizures or history of acyclovir-induced encephalopathy.
  • Caution: Elderly patients or those with mild cognitive impairment; use lowest effective dose.
  • Monitor: Electroencephalogram (EEG) if neurological symptoms arise, particularly in renal impairment.

    • Pediatric and Geriatric Considerations

    Valacyclovir dosing and safety profiles differ significantly across age groups due to physiologic variations in renal function, immune competence, and polypharmacy risks. Pediatric patients require weight-based adjustments, while geriatric patients face higher susceptibility to adverse effects and drug interactions.

    Pediatric Dosing and Monitoring

    1. Weight-Based Dosing for Children
    2. HSV Treatment: 20 mg/kg every 6 hours (max 1 g/dose) for 7–10 days.
    3. VZV Pro

      Navigating the complexities of valacyclovir therapy requires a multidisciplinary approach that integrates pharmacodynamic principles, patient-specific risk factors, and evidence-based guidelines. From avoiding high-risk drug combinations like nephrotoxic agents or CYP3A4 inhibitors to optimizing dosing windows relative to meals and beverages, each consideration plays a pivotal role in treatment success. Clinicians must remain vigilant in assessing renal function, electrolyte balance, and potential drug-drug interactions, particularly in vulnerable populations such as the elderly or immunocompromised individuals. Ultimately, this synthesis underscores the importance of personalized medicine in antiviral therapy, where informed adjustments—rooted in metabolic pathways and clinical evidence—can mean the difference between effective viral suppression and avoidable complications.

      4. FAQ

      What medications or substances should you avoid taking with valacyclovir?

      Avoid taking probenecid with valacyclovir, as it can increase drug levels and side effects. Also, limit alcohol, as it may worsen side effects like nausea or dizziness. Always check with a doctor before combining valacyclovir with other antivirals (like ganciclovir) or immunosuppressants.

      What medications or substances can you not mix with valacyclovir?

      Do not mix valacyclovir with probenecid, as it reduces kidney clearance and raises toxicity risk. Avoid high-dose nephrotoxic drugs (e.g., some antibiotics like aminoglycosides) without medical supervision, as they may strain kidneys. Alcohol and excessive caffeine can also heighten side effects.

      What should you avoid taking with acyclovir?

      Avoid probenecid with acyclovir, as it slows excretion and increases drug levels. Limit alcohol and other kidney-stressing medications (e.g., NSAIDs like ibuprofen) unless approved by a doctor. High doses of immunosuppressants (e.g., cyclosporine) may also require monitoring.

      What medications or supplements should you not take with Valtrex (valacyclovir)?

      Avoid probenecid and excessive nephrotoxic drugs (e.g., certain antibiotics or chemotherapy agents). Do not mix with high-dose live vaccines without medical advice, as valacyclovir suppresses immunity. Alcohol and St. John’s wort may also interact negatively.

      Are there specific medicines you should not take with valacyclovir?

      Yes—avoid probenecid, as it blocks valacyclovir’s excretion. Some kidney-toxic drugs (e.g., high-dose NSAIDs, aminoglycosides) should be used cautiously. Always consult a doctor before combining valacyclovir with other antivirals (e.g., ganciclovir) or immunosuppressants.

      Which supplements should you avoid while taking valacyclovir?

      Avoid St. John’s wort, as it may reduce valacyclovir’s effectiveness by altering liver enzymes. High doses of echinacea or immune-boosting herbs could theoretically interfere, but evidence is limited. Always check with a doctor before combining supplements with antiviral medications.

      Leave a Comment

      Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of Voltefac.